Use of cannabinoids in the treatment of epilepsy
US11311498B2 · kind B2 · utility
29Cited by
29References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 17, 2015 |
| Grant date | Apr 26, 2022 |
| Priority date | — |
| Expiry date | Jun 17, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.